CEOInterviews.AI
Start App
Get an email when Mark Cuban gives a new interview
One email per new interview. Unsubscribe in one click.
Mark Cuban
Co-founder; minority owner, Dallas Mavericks, Cost Plus Drugs

Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference

📅 Aug 20, 2026 Value Health Voices Podcast and Doctor Amar Explains 55 MIN 747 VIEWS 97 SEGMENTS · 3 SPEAKERS
Mark Cuban did not set out to become the most disruptive force in American drug pricing. He just wanted to know why the same generic pill could cost $15 at one pharmacy and $500 at another. In this episode of Value Health Voices, Mark tells Dr. Anthony Paravati and Dr. Amar Rewari exactly what he found when he peered under the hood of the pharmacy supply chain, and why his answer was to launch Cost Plus Drugs with a radically simple promise: show patients the real cost, add a fair markup, and sell trust instead of marketing. The conversation goes deep into the machinery most patients never se...

Questions asked in this interview

12
  1. 1:46What the [__] is going on?
  2. 2:44So, with Cost Plus Drugs, was that originally like a business opportunity for you or you were trying to attempt to prove something was broken?
  3. 5:12And I think one of the biggest things that makes trust so difficult is, like you said, when you pulled back the hood, I'm sure you discovered this concept of PBMs, right?
  4. 10:45Well, guess who, guess who gets those premiums?
  5. 12:43And when a brand medication is sold to them, these are all, each of them is multi-hundred billion dollar companies, right?
  6. 17:02But I'm wondering because the savings aren't necessarily that large for insured patients, is the benefit to Cost Plus Drugs really the drugs to the patients or is it that it benchmarks what the cost of drugs could be?
  7. 26:13You described the economic risk and you were making comments in the neighborhood of explaining the legal risk, right?
  8. 28:49What do you think about free markets and healthcare?
  9. 32:13Any other reforms you think should go?
  10. 42:09Do you think it's better to influence Washington from the outside or do you eventually think it needs to be done on the inside? What's been your takeaway?
  11. 43:27Are you going to run for president?
  12. 44:11Is it more because you don't want the job or because you don't think you could win something else?
Mark Cuban 0:00 ↗
There was somebody who came to me who had a heart transplant and they had just switched plans at their company and the new plan would not cover the everolimus for their rejection as a rejection medication and it's generic and we sell it for like $200. And so she had come to us and I was like, well, who's your employer and do they self-insure? Found out, went to the CEO and said, 'Do you realize that you have an employee who literally could die over $200 a month?' CEOs have no idea. Every day that's wasted for this person with a heart transplant without their medication is not a good day.
Anthony Parapodi 0:40 ↗
Well, back with Amar Rari, my co-host. I'm Anthony Paravati. We're the hosts of the Valley Health Voices podcast. And Amar, it's a huge day for us because we have a very exciting guest on the show that we just recorded with. He needs no introduction. He's, you know, serial entrepreneur, household name, Shark Tank, the whole deal. Mark Cuban.
Amar Rari 1:00 ↗
Oh my god, what a great episode. We're very excited for everyone to tune in. Thank you to Eric Bricker, our multiple repeat guests, who got us in touch with Mark and we've had this on the books for months. So we're very excited to share all of Mark's thoughts and actually a little preview about whether he's going to run for president or not.
Anthony Parapodi 1:17 ↗
Outstanding. Let's get right into it.
Amar Rari 1:19 ↗
I'm Dr. Amar Rari.
Anthony Parapodi 1:20 ↗
And I'm Dr. Anthony Parapodi. We are physician executives and we're the hosts of the Value Health Voices podcast. We started this podcast to break down the business and policy forces shaping American healthcare today. We talk with the people shaping these decisions and we bring a perspective from both the front lines of patient care and the C-suite.
Amar Rari 1:38 ↗
Our goal is simple. Give you clear, practical insights to help you lead in a system that's constantly changing. Let's get into it.
Well, Mark, you're on the Value Health Voices podcast and we couldn't start any other place but to bring up something that I think got you interested in healthcare and that is the fact you can buy the same exact drug in the United States for massively different prices, say $15 or $500, depending on who's paying, where it's purchased, or what intermediary sits between the patient and the manufacturer. As an entrepreneur, as a businessman, when you first peered under this hood and really understood how prescription drugs are priced, tell us how you reacted. What the [__] is going on? [laughter]
Mark Cuban 2:21 ↗
That was my reaction because it made no sense to me whatsoever. I mean, I could see it if you're selling, you know, Ferraris and you customize them, right? But you're talking about particularly generics. There's no good reason for there to be a delta in pricing depending on who you are, where you are, what time of day, what pharmacy. It made no sense, which is why we started costplusdrugs.com.
Anthony Parapodi 2:44 ↗
So, with Cost Plus Drugs, was that originally like a business opportunity for you or you were trying to attempt to prove something was broken?
Mark Cuban 2:51 ↗
All the above. You know, when we looked at it, it was obviously going to be a business opportunity because there's an infinite number of examples of people walking up to the pharmacy counter and having to turn around because they didn't realize or didn't know what the price would be and then came to realize they couldn't afford to purchase it. And we've all heard those horror stories. And so, we knew the market was there. It was just a question of what's the best way to deal with it. And really, this all comes down to trust. I think that was the underlying principle. When you don't know the price of something, trust is actually an equation. Trust equals transparency as the numerator and self-interest as the denominator. And when we launched, you know, complete transparency. We showed you our actual cost and we showed you our markup. We showed you everything. And our markup was only 15%, which I think everybody believes to be fair, just enough to give us a chance to try to break even. And because of that, people trusted us. And when we first got started, you know, and we were hiring people, people were like, 'We need marketing. We need this. We need...' I'm like, 'No, you don't understand. We don't sell drugs. We sell trust. Drugs just happens to be a byproduct of that trust.' And so that's what led us to starting and that's what's helped us grow, you know, significantly since January of '22.
Amar Rari 4:12 ↗
For those who aren't familiar with the Cost Plus Drugs model, help us understand, help the listener understand why it is that you can sell drugs so much more cheaply than if a patient obtains the same drug through their insurance benefit.
Mark Cuban 4:27 ↗
Because we're not marketing to market. I'm marketing to be fair and I'm marketing to maximize how many people we help as opposed to trying to fill a fiduciary responsibility to shareholders. And so that's one key reason I don't need to make the money. Whereas you look at different carriers who are all these huge vertically integrated conglomerates and their only mission, they say they want to help patients, but their primary mission is to maximize earnings. And so that was the primary difference. We could have come in and just said, okay, we're going to underprice everybody else and just look cheaper. But that wouldn't garner trust because if they're 700 and we priced at 650, that's not going to be life-changing for people who can't afford their medications.
Anthony Parapodi 5:12 ↗
Yeah. And I think one of the biggest things that makes trust so difficult is, like you said, when you pulled back the hood, I'm sure you discovered this concept of PBMs, right? And so everything from rebates to spread pricing, it's so difficult for anybody to understand. So maybe kind of walk us through a little bit about what were your thoughts when you came across PBMs when you first looked at this.
Mark Cuban 5:33 ↗
That it's a scam, that it's ridiculous, that they take advantage of employers, of patients, of doctors, you name it. There's nobody that they don't try to take advantage of. And actually, one of my biggest mistakes early on was looking at PBMs as individual entities. In reality, they're part of much larger conglomerates. And what I've learned over the years is if the culture you have for one of your subsidiaries is the same culture you have throughout all your subsidiaries and all your affiliates. And you know, you talked about, I think you talked about pricing off the bat. We can talk about a drug being priced differently depending on the patient, etc. You can talk about a hip replacement being priced differently and everything else. And what you see is the same thing applies to every one of the thousands of subsidiaries some of these companies have. And so knowing this and noticing that, it really just became an effort to get in front of patients. And we don't spend any money on marketing. Now, obviously I have a platform and a big mouth, but when you know, you see somebody who saves $1,900 on, you know, on one generic specialty drug. And by the way, if it's a tablet, there's nothing special about it. It's just a reason for a PBM to charge more. And that really was what put me in tune. If I saw these specialty tablets being priced as if there's something unique and differentiated about them when in reality we can buy the same Gleevec for, you know, a Gleevec 400 for 20 bucks and sell it for 23 or whatever it is, right? It just made no sense whatsoever. And that really is what propelled us. And as I alluded to, we don't spend money on marketing, but I knew that if I save somebody $500, $100, $50, $20, right? What are they going to do? They're going to tell their family, their friends, they're going to tell everybody else in the Facebook group that has the same disease state as they do. They're going to tell their doctors, and one by one, they'll tell other people in similar circumstances. And that's what blew up costplusdrugs.com.
Amar Rari 7:42 ↗
Mark, I think all the work you did helped crystallize for the public and to some extent policymakers a fundamental conflict of interest in the PBM game. I mean, there's truly a fundamental conflict of interest that it took you to crystallize it is sort of surprising because it's really not that hard to understand.
Mark Cuban 7:57 ↗
It is surprising. [laughter]
Amar Rari 7:59 ↗
Yeah. I'm saying, I'm saying it's actually not surprising to me because...
Mark Cuban 8:05 ↗
I'm the guy who came in from the outside, right, to do it.
Amar Rari 8:08 ↗
Oh, exactly. The Shark guy. Yeah.
Mark Cuban 8:10 ↗
Yeah. Well, it's like, yeah. And sometimes it takes the outsider where there's an obvious problem business and you got to pay big money.
Amar Rari 8:16 ↗
No, you're exactly right. Tell you...
Mark Cuban 8:18 ↗
And I'll give you the exact, I'll give you an example. When we came in, we had the opportunity to work with the big PBMs to try to sell more, maybe even to get some better prices on brands. We chose not to because they were the source of the problem. And so because of that, we don't have access to many brands. I think we have 79 brands in total on costplusdrugs.com when there's, you know, hundreds if not thousands of brand and specialty drugs we don't carry. And the reason we don't carry them is because those PBMs and those vertically integrated companies have gone to the brand and specialty manufacturers and said, 'Don't sell to Cost Plus Drugs. If you do, we will diminish your positioning on our formularies for your entire portfolio.' And so they're not, you know, the brands aren't dumb. They'll tell me, 'Mark, we love you. We support you, but I can't lose hundreds of millions or more in sales just to deal with you.'
Amar Rari 9:17 ↗
Yeah. And for the listeners who might not be intimately familiar with this, what Mark is talking about is that the PBM sits between, this is what I was talking about, about the conflict of interest. They have two customers. They have the drug manufacturer, right, who's paying them and they have health plans paying them. And the interest of the health plan and the interest of the manufacturers are diametrically opposed, right? So, so the PBMs, and this is what was blown up in the, or it's in the process of being blown up in a law that I think, Mark, you had a role in helping get over the finish line, the Consolidated Appropriations Act of this year ends this rebate model eventually for the PBMs. But so on the drug manufacturer side, the drug manufacturers want the favorable formulary pricing, right? And so they pay big money rebates and that's where the opacity comes in. Nobody knows what they're paying. They pay those rebates to the third-party PBM and then at the same time the health plan, which ultimately is, has the patient as the customer, also has to pay the third-party PBM to manage the...
Mark Cuban 10:10 ↗
And you realize in the case of CVS Caremark they own the insurance company and in the case of United and others they own the PBM and so it's just right pocket, left pocket more often than not and it's crazy. Even the CBO has fallen for that. So when you talk to the CBO and then you discuss rebates, the CBO will come out and say, 'Well, if you get rid of rebates, then premiums will go up because they're using supposedly the companies are using those rebates to buy down premiums.'
Amar Rari 10:45 ↗
Well, guess who, guess who gets those premiums?
Mark Cuban 10:50 ↗
Yeah. The insurance company that either owns or is owned by the PBM. So, they're just sliding it to somebody else. And let me just tell you, no matter what happens with rebates, that insurance company is not going to reduce their premiums. There is no world where that happens, right?
Amar Rari 11:06 ↗
And the other thing is it's not just insurance company because, you know, if you get rid of the PBMs or at least just make them more of a claims processing thing, like you said, this is vertically integrated companies, that margin has to move somewhere, whether specialty pharmacy or the insurer or the... like it might go somewhere else.
Mark Cuban 11:25 ↗
Just look at the numbers when they go, when they have their public, when they report their earnings as public companies, right? They're saying, 'Yeah, our rebates are going down and we anticipate these changing.' They're not saying we're going to make less money. They're showing you that they're, you know, they're pushing people to their own specialty pharmacy where the margins are enormous, right? And what they're saying in their contracts and separately is, okay, if we don't have rebates, we'll just make it up in fees. So, we're going to charge you an administrative fee for all your people on statins. We're going to charge a different fee, a medical management fee for people with CKD. We're going to charge you a $2 per member per month for anybody in the state of Florida because Florida's changed their reporting laws and we have to compensate for that. So, you may not, they may not get rebate money, right? But they're making it up elsewhere. And the telltale as somebody who's dealing with legislation is how drugs are sold, brand drugs are sold to the big three distributors. There's three major distributors that deal with 95% of the drug transactions in this country, right?
Amar Rari 12:43 ↗
And when a brand medication is sold to them, these are all, each of them is multi-hundred billion dollar companies, right? They're enormous.
Mark Cuban 12:50 ↗
And so when they negotiate prices for a brand medication, you would think they'd be able to get a decent price. But you would be wrong. When those brands, BMS, Pfizer, Lilly, whoever, sell to each of those big distributors, wholesalers, they sell at WAC, basically list price, and then they get kickback, is the right word, for paying early and for giving data. They receive about 5% back. And so effectively, they're paying 95% of list price. Now, why does that happen? Because if there's going to be no more rebates, they're effectively supposed to go away. Rebates just add to the overhead associated with dealing with the transaction at every single level. If rebates truly were going away, then the PBM/insurance companies would go to the manufacturers, brand manufacturers, and say, 'Look, now's the time to switch to selling to those wholesalers at a net price plus some markup.' But they're not doing that. And here's the downside of that not happening. Let's just use an anticoagulant that has a $600 list price as an example, right? So now that big wholesaler after they pay 600, got 5% back, they're out of pocket $570. That wholesaler sells that drug, that anticoagulant, to a pharmacy for $570. They can't sell for less than their cost. So if that pharmacy is paying $570, someone comes in without insurance, someone comes in with a high deductible, they can't sell for less than what they paid for at $570. But if the rebate and all fees nets out to be, let's just say $300 to make the math easy. If the brand manufacturer had sold to the wholesaler at $325, let's say, right now the wholesaler could charge $350, make more money, the manufacturer makes more money, and now the pharmacies can sell to every uninsured individual for $340, right? $350. And that can be the difference between them getting life-saving medication or not. But that's not happening until you see how drugs are sold to wholesalers. All the [__] about, well, we're not doing rebates anymore, is total [__]. And when you talk to, and I've talked to CEOs and CFOs and, you know, and other people in the C-suite of these brand manufacturers and I'm like, why do you do this? You literally have patients who can't afford their medications who during their deductible phase, the beginning of the year, if you have a $2,500 deductible and this anticoagulant is $600, there's a very strong likelihood you're paying $600 a month and you may not be able to afford it. And so why is it that you're willing to accept these terms and not be able to reach as many potential patients and making less per script, per drug? And they're like, 'Mark, we have been told just like they told us about you and working with you, they're not going to, they're going to diminish us on the formulary.' They say the exact same thing in how we deal with the wholesalers. If we sell to them at $340 instead of $570, that delta is the money that's held for rebates, all that is the rebate. And if we don't live up to that and allow them to use that rebate, they're going to hit us on the formulary or somewhere else. And so even though legislatively with, you know, these things are passing, Department of Labor, states, everybody playing these tricks, you can't reroute to your own pharmacy, that's all great and good, but until you see wholesalers change the way they buy brands and specialty, it's all [__].
Anthony Parapodi 17:02 ↗
Yeah. Yeah. Actually, you brought up a good point that I wanted to talk about. So Cost Plus Drugs, obviously very transparent. You can go on the website and you can see these amazingly cheap drugs, particularly for high-cost drugs like you said in the oncology space or anticoagulation, all that. But on the generic front, I know there was a study in '24 from JAMA looking at Cost Plus Drugs, right? And they saw about a 5.5% savings for Medicare patients, 7.1% savings for private insurance, and 28% savings for uninsured patients. So huge for uninsured. But I'm wondering because the savings aren't necessarily that large for insured patients, is the benefit to Cost Plus Drugs really the drugs to the patients or is it that it benchmarks what the cost of drugs could be? And so legislation and Congress and everybody can look at Cost Plus now when they're trying to create reforms and be like, this is why our system is so out of whack.
Mark Cuban 18:03 ↗
Well, there's a couple pieces there, right? I don't know the exact percentage, but a big chunk of drugs, generic drugs, tableted drugs, cost five bucks or less. And if our shipping for the first script is $5, it's going to be cheaper. And those typically have zero out-of-pocket from any insurance carrier, right? Medicare Advantage, Medicare, you know, corporate insurance, ACA. So for us to compete with zero, that kind of skews the numbers, right? And the second part of that is when they did that, in most studies for that matter, and we keep on trying to correct them, the first script that you have with Cost Plus, the shipping is $5. But if you add a second script, third script, the shipping is still $5. It's when you get to the fourth script, then it adds another $2.50. Now the shipping is $7.50. So the cost per script goes down when you have more than one. And that wasn't accounted for in those studies. And beyond that, in terms of benchmarking, yes, you know, I sat in front of a Senate committee and the guy who runs CalPERS was there and he said, 'Look, we use Cost Plus Drugs price list to tell CVS, you've got to beat these prices.' And in terms of savings, we see it all the time. People who are on Part D Medicare or Medicare Advantage where they're specialty generics, they're getting charged coinsurance because it's tier five and we're almost always cheaper. And now you're seeing it with biosimilars where the PBMs are using those as a source of margin where they're actually working with companies to manufacture their own white label versions. And so what you know, for a Stelara biosimilar, you know, the brand might have been, let's say, $12,000 a month for easy numbers, right? And their version might be $1,000 a month and they're saying, 'Hey, we're saving you 90%.' And our version is $365 plus shipping, right? And so, you know, it really depends on where your focus is. We're almost always going to save employers, everybody, uninsured, underinsured money on anything that costs more than $25.
Amar Rari 20:21 ↗
Rolling with the punches here, guys. I lost power. Crazy storm's rolling through Ohio. So, I flipped over to my phone. Crazy timing, Mark, for the bad weather, but we just, we'll just roll with it.
Mark Cuban 20:30 ↗
Hey, that's how you do it.
Amar Rari 20:33 ↗
So, we'll roll with it.
Mark Cuban 20:34 ↗
That makes it more interesting.
Amar Rari 20:35 ↗
So, maybe we'll leave a little bit of this in here so that people know why I look so bizarre on my phone here in the dark. But...
Mark Cuban 20:42 ↗
I think you look better.
Amar Rari 20:43 ↗
I look better. Thanks. Yeah. So I had, before I had my power issue, I was starting to ask you about how what you've done in Cost Plus Drugs changed the policy conversation around the pharmacy supply chain and drug prices. And so I wanted to know, Mark, if you felt that your, I mean, you've obviously testified, to what extent the voice you have, the platform you have, Cost Plus Drugs deserves credit for changing the conversation and driving real reforms.
Mark Cuban 21:09 ↗
I think we've certainly impacted the conversation and changed the conversation. And I think it's not just how we do business, but it's the fact that we'll call [__], right? We're not afraid to speak to power when the PBMs and the carriers, you know, do crazy stuff like, you know, they won't let you audit your claims. I literally spend more of my time talking to CEOs and CFOs and telling them to take their PBM and ASO, the third-party administrator contracts, and just run them through Claude and just prompt it and say, 'Where am I getting ripped off?' So, right, because they have no...
Amar Rari 21:49 ↗
Actually, this is exactly what I had in mind when I brought up that bit about the conflict of interest. And I wasn't bringing it up because the big three PBMs own insurance companies for fully insured plans. I was bringing that up because they're screwing the ultimate payer who is self-insured, right? And that was always my understanding of how you got into it because you were seeing your own companies get screwed by these guys.
Mark Cuban 22:12 ↗
Yeah, absolutely. Yeah. And mine was just a broker. We weren't using a PBM. I had a broker that was my guy that always did my health benefits for all my companies for decades from the time I was in my 20s. And when I got to the Mavs and did a quick comparison of generics that we were paying over $30 for at the Mavs versus what the cost at Cost Plus Drugs was. And this is when we only had 111 drugs and our prices were as high as they ever were. Right. And what we spent, I think it was $169,000 at the Mavs would have cost me $19,000 at Cost Plus. And so that was the best, you know, the best fact case that something's really amiss here. And then as you get into it, you realize that 67% of employees with insurance get it from self-insured employers. And it's those self-insured employers who are hiring the PBMs and ASOs and carriers to supposedly act in their best interest because the economic risk is still in the hands of the employer. So you would think that these companies that they contract with, the PBMs, the ASOs, are going to just go to the ends of the earth to get them the best price. And it's the exact opposite that happens. You know, they won't let them audit things. They won't let them pre-review claims before they're sent in. If you try to audit, they'll say, 'You have to use our own internal auditor.' You know, and I've never talked to a company who was able to get an audit done who said they paid too little and had to refund money back. They all get ripped off, you know, and there's just so many comparable examples of the same thing. So I say to these CEOs, 'Why are you letting yourself get ripped off? It makes absolutely no sense. You have fiduciary responsibility not just to your shareholders who you're letting down, but also to your employees and their families who you're letting down.' And I'll give you the latest example. Like there was somebody who came to me who had a heart transplant and they had just switched plans at their company and the new plan would not cover the everolimus for their rejection as a rejection medication and it's generic and we sell it for like $200. And so she had come to us and I was like, well, who's your employer and do they self-insure? Found out, went to the CEO and said, 'Do you realize that you have an employee who literally could die over $200 a month?'
Amar Rari 24:48 ↗
I had no idea.
Mark Cuban 24:49 ↗
CEOs have no idea. If they were hiring people who truly cared, they'd be going to the CEOs and saying, 'Look, this is your decision. Your guidelines that you gave us say that we're not supposed to cover this or we're supposed to pre-auth it or we're supposed to deny it, but we'd like for you to make the decision because every day that's wasted for this person with a heart transplant without their medication is not a good day.' Every time somebody with cancer gets a denial and the doctor, you guys know this better than anybody, has to do a peer-to-peer, their odds of recovering decline. Yet, it's ultimately in the hands of the CEO of the self-insured employer, and they have no idea. These are just ongoing examples that I explain to those CEOs. And then to make matters worse, they turn around more often than not and say, 'Well, it's in the hands of HR.' And then you go and you talk to HR and literally I had one say, 'Well, I got to trust somebody, Mark. I don't know who to trust.' I'm like, 'Look, they are ripping you off.' And like, we know we're losing money. We know we're getting ripped off. But do you know how hard it is to have tens of thousands of members or more and trying to convince them that it's good to change the logo on their insurance card? They don't want to deal with it. It's just, it's crazy.
Amar Rari 26:13 ↗
What you're talking about, there's been some folks, especially with fairly big platforms, not as big as yours on LinkedIn, who've described this situation. You described the economic risk and you were making comments in the neighborhood of explaining the legal risk, right? Because what it actually is, is a risk to the head of HR. It's a risk to the CFO and the CEO of these companies if they breach fiduciary responsibility.
Mark Cuban 26:34 ↗
Especially now. Yeah, it's a huge deal and there's been some big cases. One was involving Kraft Heinz and a few other ones. And finally, and this happened around the same time you started Cost Plus Drugs, by the way, some of these big cases. And so people are starting to understand, but for every CEO or CFO or HR leader who does understand, there's another 50 who don't. So that's why I think it's worth...
Amar Rari 26:56 ↗
Yeah, and I think those ERISA lawsuits where they use our pricing to show that they overpaid significantly...

48 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Cuban, M. (2026, August 20). Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference [Interview transcript]. Value Health Voices Podcast and Doctor Amar Explains. CEOInterviews.AI. https://ceointerviews.ai/interview/3054517/

MLA

Mark Cuban. "Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference." Value Health Voices Podcast and Doctor Amar Explains, 20 Aug. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3054517/.

BibTeX
@misc{cuban2026_3054517,
  author       = {Mark Cuban},
  title        = {Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference},
  howpublished = {Interview transcript, Value Health Voices Podcast and Doctor Amar Explains. CEOInterviews.AI},
  year         = {2026},
  month        = {aug},
  url          = {https://ceointerviews.ai/interview/3054517/},
  note         = {Speaker-attributed transcript with timestamps}
}